Symbiotec Pharmalab IPO Day 2 LIVE: GMP jumps! Subscription status, review, issue size, other details; should you apply?

Symbiotec Pharmalab IPO Day 2 LIVE: Bidding for the initial public offering (IPO) of Symbiotec Pharmalabs Ltd opened on 24 August 2026. The public issue will remain open for bidding until 26 August 2026. The company has declared the Symbiotec Pharmalab IPO price band at ₹938 to ₹988 per equity share. Symbiotec Pharmalab IPO subscription will remain open from 10:00 AM to 5:00 PM on all trade dates during the Symbiotec Pharmalab IPO date. Symbiotec Pharmalab' IPO size is ₹1,757 crore, which is a mix of fresh issue and Offer for Sale (OFS). Looking at the IPO size, the issue received a decent response from investors. According to the Symbiotec Pharmalab IPO subscription status, the public issue worth ₹1,757 crore was booked 80%. Meanwhile, Symbiotec Pharmalab IPO GMP (Grey Market Premium) is signalling a bumper listing gain of around 41%.

Symbiotec Pharmalabs IPO GMP today

According to market observers, the company shares are available at a premium of ₹409 in the grey market today. This means Symbiotec Pharmalabs IPO GMP today is ₹409, signalling a 41% listing pop against the upper price band of the public issue. So, after the end of bidding on day 1, Symbiotec Pharmalabs IPO GMP has risen from ₹345 to ₹409.

Symbiotec Pharmalabs IPO subscription status

By 12:48 PM on day 2, the public issue was booked 1.35 times, the retail portion was filled 1.58 times, whereas the NII segment was subscribed to 1.90 times. The QIB portion was subscribed to 0.54 times.

Symbiotec Pharmalabs IPO details

Here we list out important Symbiotec Pharmalabs IPO details in 10 points:

1] Symbiotec Pharmalabs IPO GMP today: According to market observers, shares of the company are available at a premium of ₹345 in the grey market today.

2] Symbiotec Pharmalabs IPO date: The public issue has opened today and will remain open until 26 August 2026.

3] Symbiotec Pharmalabs IPO price: The company management has offered Symbiotec Pharmalabs shares at a price band of ₹938 to ₹988 per equity share.

4] Symbiotec Pharmalabs IPO size: The company aims to raise ₹1.757 crore, out of which ₹150 crore is aimed through the issuance of fresh shares only. The remaining ₹1,607 crore is reserved for the OFS route.

5] Symbiotec Pharmalabs IPO lot size: A bidder will be able to apply for the public issue in lots, and one lot of the public offer comprises 15 company shares.

6] Symbiotec Pharmalabs IPO allotment date: The tentative date for the finalisation of share allotment is 27 August 2026.

7] Symbiotec Pharmalabs IPO registrar: MUFG Intime India Private Ltd has been appointed the official registrar of the book build issue.

8] Symbiotec Pharmalabs IPO listing date: The public issue is proposed for listing on the BSE and NSE exchanges. The most likely date for the share listing is 1 September 2026.

9] Symbiotec Pharmalabs IPO lead managers: JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory & Securities (India) have been appointed lead managers of the Behari Lal Engineering IPO.

Symbiotec Pharmalabs IPO review

10] Should you subscribe to Symbiotec Pharmalabs IPO: Assigning an ‘apply’ tag to the book-building issue, Mahesh M Ojha, VP — Research & Business Development at KC Securities, said, “Symbiotec Pharmalab Ltd. is an integrated, backwards-integrated pharmaceutical and biotechnology platform focused on steroidal hormone and corticosteroid APIs, nutritional ingredients and speciality products, serving over 40 countries.”

Mahesh M Ojha of KC Securities said the company exports 60+ APIs, with 67.04% of FY26 revenue generated from international markets, supported by approvals from the US FDA, EU-GMP, Korea MFDS, and other global regulators. Its manufacturing footprint includes two established API facilities at Rau and Pithampur, complemented by recently commissioned facilities at Ujjain and Mhow, with a workforce of 2,500+ employees, including 156 R&D scientists.

“At 58.36x post-IPO FY26 P/E, the valuation appears relatively attractive versus listed peers. Hence, we recommend Investors to subscribe for a long-term horizon,” Ojha added.

Disclaimer: This story is for educational and informational purposes only. The views and recommendations above are those of individual analysts or broking companies, not Mint. We advise investors to check with certified financial experts before making any investment decisions.